Method of treating fibroproliferative disorders

Details Method of treating fibroproliferative disorders Method of treating fibroproliferative disorders

2007-02-06

2007-02-06

Kemmerer, Elizabeth (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S139100, C424S141100, C424S145100

Reexamination Certificate

active

10606055

ABSTRACT:
Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.

REFERENCES:
patent: 5238950 (1993-08-01), Clader et al.
patent: 5700823 (1997-12-01), Hirth et al.
patent: 6264949 (2001-07-01), Friedman
patent: 6455283 (2002-09-01), Ferrara et al.
patent: 6495668 (2002-12-01), Gilbert et al.
patent: 6706687 (2004-03-01), Eriksson et al.
patent: 2002/0094546 (2002-07-01), Shimkets et al.
patent: 2003/0049816 (2003-03-01), Baker et al
patent: 2004/0242850 (2004-12-01), Gilbert et al.
patent: 00/27879 (2000-05-01), None
patent: 00/34474 (2000-06-01), None
patent: 00/59940 (2000-10-01), None
patent: 00/66736 (2000-11-01), None
patent: 01/00878 (2001-01-01), None
patent: 01/40466 (2001-06-01), None
patent: 01/55430 (2001-08-01), None
patent: WO02/058716 (2002-08-01), None
Hamada et al., Biochem. Biophys. Res. Comm. 2001; 280: 733-737.
Eitner and Floege, Curr Opin Investig Drugs. 2005; 6: 255-61.
Coppo and Amore, Pediatr Nephrol. 2004; 19:256-65.
Booy et al., Arch Immunol. Ther. Exp., 2006, 54, 85-101.
Ostendorf et al. J Am Soc Nephrol. 2006; 17: 1054-62.
Ostendorf et al. J Am Soc Nephrol. 2003; 14: 2237-47.
Glomerulonephritis; Definition and Much More from Answers.com. (3 pages; accessed May 18, 2006).
Bessho et al. Am J Physiol Renal Physiol. 2003; 284: F1171-F1180.
Hudkins et al. J Am Soc Nephrol. 2004; 15: 286-298.
Taneda et al. J Am Soc Nephrol. 2003; 14: 2544-2555.
Preaux et al.,Hepatology 26: 315-322, 1997.
Pinzani et al.,British Journal of Pharmacology 119: 1117-1124, 1996.
Isbrucker et al.,Toxicology and Applied Pharmacology 149: 120-126, 1998.
Friedman,Seminars in Liver Disease 19: 129-140, 1999.
Li et al., Journal ofGastroenterology and Hepatology 14: 618-633, 1999.
Brady et al.,Biochemical and Biophysical Research Communications 248: 174-179, 1998.
Heldin et al.,Physiological Reviews 79: 1283-1316, 1999.
Johnson et al.,J. Exp Med. 175: 1413-1416, 1992.
Deuel et al.,New England Journal of Medicine 317: 236-237,1987.
Eddy,Pediatr. Nephrol. 15: 290-301, 2000.
Powell et al.,American Journal of Physiology 277: C1-C19, 1999.
Tsai et al.,Biochimica et Biophysica Acta 1492: 196-202, 2000.
Smits et al.,American Journal of Pathology 140: 639-648, 1992.
Eng et al.,Extracellular Matrix in the Kidney 107: 156-162, 1994.
Uutela et al.,Circulation 103: 2242-2247, 2001.
LaRochelle et al.,Nature Cell Biology 3: 517-521, 2001.
Bergsten et al.,Nature Cell Biology 3: 512-516, 2001.
Floege et al.,J. Clin. Invest. 92: 2952-2962, 1993.
Yi et al.,Am. J. Pathol. 149: 539-548, 1996.
Rice et al.,Am. J. Pathol. 155:213-221, 1999.
Johnson et al.,J. Exp. Med. 175: 1413-1416, 1992.
Yoshida et al.,Biochem. Biophys. Res. Commun. 265: 503-508, 1999.
Isaka et al.,J. Clin. Invest. 92: 2597-2601, 1993.
Martinet et al.,N. Engl. J. Med. 317: 202-209, 1987.
Yagi et al.,Gen. Pharmac. 31: 765-773, 1998.
Kallio et al.,Am. J. Respir. Crit. Care Med. 160: 1324-1332, 1999.

Affiliated with

Also associated with

Rating

Method of treating fibroproliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating fibroproliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating fibroproliferative disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3836390